US Pharma MarketingAstraZeneca gains 2nd bladder cancer nod in key expansion for Imfinzi
AstraZeneca gains 2nd bladder cancer nod in key expansion for Imfinzi is a pharma and life sciences industry update from FiercePharma. The story may affect commercial strategy, market access planning, stakeholder engagement, competitive positioning, and near-term monitoring for pharmaceutical and biotech teams.
AstraZeneca has fired another shot in its bladder cancer competition with Merck’s Keytruda, with the FDA clearing its PD-L1 inhibitor Imfinzi, used alongside standard of care, to become the first immunotherapy combination regimen for patients with with high-risk non-muscle-invasive bladder cancer.
Source: FiercePharma